Biofrontera

Biofrontera Accounts Payable

The Accounts Payable of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 1.46 M EUR. In the previous year, Accounts Payable was 2.12 M EUR — a change of -31.26% (lower).

Accounts Payable

1.46 MEUR

YoY

-31.26%

Last updated:

Accounts Payable of Biofrontera is 2025 1.46 M EUR. Accounts Payable of Biofrontera was 2024 2.12 M EUR. It decreases by -31.26% lower compared to the previous year.

The Biofrontera Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
1.81 M EUR
Jan 1, 2019
4.20 M EUR
Jan 1, 2020
1.62 M EUR
Jan 1, 2021
2.74 M EUR
Jan 1, 2022
1.98 M EUR
Jan 1, 2023
2.59 M EUR
Jan 1, 2024
2.12 M EUR
Jan 1, 2025
1.46 M EUR
The Biofrontera Accounts Payable history
YEARAccounts PayableYoY
1.46 MEUR-31.26%
2.12 MEUR-18.12%
2.59 MEUR+30.75%
1.98 MEUR-27.46%
2.74 MEUR+68.52%
1.62 MEUR-61.32%
4.20 MEUR+132.34%
1.81 MEUR+66.61%
1.08 MEUR-48.21%
2.09 MEUR+100.60%
1.04 MEUR+7.85%
967,437.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Accounts Payable of Biofrontera is 1.46 M EUR in 2025.

Accounts Payable of Biofrontera changed from 2.12 M EUR to 1.46 M EUR, representing a -31.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biofrontera

All Key Metrics — Biofrontera